|
Market Closed -
Other stock markets
|
After hours 03:59:59 pm | |||
| 47.98 EUR | -0.58% |
|
48.06 | +0.17% |
| Jan. 14 | Recordati Industria Chimica e Farmaceutica S.p.A. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-14-2026 11:15 AM | |
| Jan. 12 | Recordati Acquires 74,165 Own Ordinary Shares | AN |
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 10.77 | 11.41 | 9.99 | 9.54 | 9.34 | |||||
Return on Total Capital | 12.76 | 13.32 | 12.01 | 11.53 | 11.08 | |||||
Return On Equity % | 28.69 | 29.04 | 21.34 | 24.08 | 23.38 | |||||
Return on Common Equity | 28.69 | 29.05 | 21.34 | 24.08 | 23.38 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 71.92 | 72.93 | 72.11 | 71.15 | 69.94 | |||||
SG&A Margin | 29.13 | 30.44 | 30.88 | 28.89 | 27.96 | |||||
EBITDA Margin % | 38.58 | 37.48 | 35.57 | 36.36 | 36.39 | |||||
EBITA Margin % | 37.53 | 36.51 | 34.69 | 35.55 | 35.53 | |||||
EBIT Margin % | 32.82 | 31.93 | 29.38 | 30.09 | 29.82 | |||||
Income From Continuing Operations Margin % | 24.5 | 24.43 | 16.85 | 18.69 | 17.79 | |||||
Net Income Margin % | 24.5 | 24.43 | 16.85 | 18.69 | 17.79 | |||||
Net Avail. For Common Margin % | 24.5 | 24.43 | 16.85 | 18.69 | 17.79 | |||||
Normalized Net Income Margin | 19.94 | 18.9 | 17 | 16.76 | 16.38 | |||||
Levered Free Cash Flow Margin | 11.25 | 24.77 | 11.48 | 1.56 | -16.34 | |||||
Unlevered Free Cash Flow Margin | 12 | 25.6 | 12.64 | 3.8 | -14.17 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.52 | 0.57 | 0.54 | 0.51 | 0.5 | |||||
Fixed Assets Turnover | 10.87 | 11.95 | 12.77 | 12.33 | 12.15 | |||||
Receivables Turnover (Average Receivables) | 5.12 | 5.48 | 5.53 | 5.16 | 4.87 | |||||
Inventory Turnover (Average Inventory) | 1.7 | 1.78 | 1.58 | 1.45 | 1.54 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 1.34 | 1.36 | 1.28 | 1.2 | 1.61 | |||||
Quick Ratio | 0.82 | 0.95 | 0.77 | 0.76 | 1.02 | |||||
Operating Cash Flow to Current Liabilities | 0.7 | 0.78 | 0.5 | 0.48 | 0.61 | |||||
Days Sales Outstanding (Average Receivables) | 71.47 | 66.61 | 65.94 | 70.74 | 75.18 | |||||
Days Outstanding Inventory (Average Inventory) | 215.07 | 204.8 | 230.47 | 251.81 | 236.96 | |||||
Average Days Payable Outstanding | 130.54 | 139.63 | 103.16 | 153.37 | 127.4 | |||||
Cash Conversion Cycle (Average Days) | 156.01 | 131.77 | 193.26 | 169.18 | 184.74 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 83.9 | 72.84 | 112.14 | 108.45 | 132.68 | |||||
Total Debt / Total Capital | 45.62 | 42.14 | 52.86 | 52.03 | 57.02 | |||||
LT Debt/Equity | 60.98 | 55.04 | 86.76 | 80.24 | 115.82 | |||||
Long-Term Debt / Total Capital | 33.16 | 31.85 | 40.9 | 38.5 | 49.78 | |||||
Total Liabilities / Total Assets | 52.93 | 50.94 | 61.33 | 59.93 | 63.45 | |||||
EBIT / Interest Expense | 27.17 | 24.14 | 15.81 | 8.42 | 8.6 | |||||
EBITDA / Interest Expense | 32.52 | 28.81 | 19.46 | 10.33 | 10.66 | |||||
(EBITDA - Capex) / Interest Expense | 31.3 | 27.76 | 18.76 | 9.93 | 10.21 | |||||
Total Debt / EBITDA | 1.88 | 1.67 | 2.59 | 2.38 | 2.88 | |||||
Net Debt / EBITDA | 1.55 | 1.27 | 2.16 | 2.09 | 2.5 | |||||
Total Debt / (EBITDA - Capex) | 1.95 | 1.73 | 2.68 | 2.47 | 3 | |||||
Net Debt / (EBITDA - Capex) | 1.61 | 1.31 | 2.24 | 2.17 | 2.62 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | -2.23 | 9.06 | 17.29 | 12.36 | 12.45 | |||||
Gross Profit, 1 Yr. Growth % | -0.28 | 10.59 | 15.97 | 10.86 | 10.54 | |||||
EBITDA, 1 Yr. Growth % | 3.82 | 5.94 | 11.31 | 14.85 | 12.54 | |||||
EBITA, 1 Yr. Growth % | 3.76 | 6.07 | 11.46 | 15.15 | 12.37 | |||||
EBIT, 1 Yr. Growth % | 0.95 | 6.11 | 7.91 | 15.08 | 11.46 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | -3.75 | 8.71 | -19.08 | 24.61 | 7.01 | |||||
Net Income, 1 Yr. Growth % | -3.75 | 8.73 | -19.08 | 24.61 | 7.01 | |||||
Normalized Net Income, 1 Yr. Growth % | 2.69 | 3.38 | 5.52 | 10.75 | 9.92 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | -3.74 | 8.72 | -19.07 | 24.56 | 7.04 | |||||
Accounts Receivable, 1 Yr. Growth % | -9.45 | 14.46 | 17.58 | 23.02 | 16.07 | |||||
Inventory, 1 Yr. Growth % | 10.74 | -8.96 | 85.4 | -4.54 | 25.1 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | -0.07 | -1.6 | 21.4 | 12.23 | 15.7 | |||||
Total Assets, 1 Yr. Growth % | -3.46 | 3.86 | 41.99 | 5.23 | 22.01 | |||||
Tangible Book Value, 1 Yr. Growth % | 27.35 | -27.69 | 248.2 | 10.84 | 41.34 | |||||
Common Equity, 1 Yr. Growth % | 6.46 | 8.28 | 11.92 | 9.06 | 11.29 | |||||
Cash From Operations, 1 Yr. Growth % | 26.63 | 21.82 | -6.09 | 5.12 | 17.43 | |||||
Capital Expenditures, 1 Yr. Growth % | -3.77 | 2.77 | 9.31 | 24.28 | 23.44 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | -240 | 140.17 | -45.64 | -84.69 | -1.27K | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | -267.47 | 132.57 | -42.08 | -66.24 | -519.54 | |||||
Dividend Per Share, 1 Yr. Growth % | 5 | 4.76 | 4.55 | 4.35 | 5.83 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 3.51 | 3.26 | 13.1 | 14.8 | 12.4 | |||||
Gross Profit, 2 Yr. CAGR % | 4.37 | 5.01 | 13.25 | 13.39 | 10.7 | |||||
EBITDA, 2 Yr. CAGR % | 5.58 | 4.88 | 8.6 | 13.07 | 13.69 | |||||
EBITA, 2 Yr. CAGR % | 5.61 | 4.91 | 8.73 | 13.29 | 13.75 | |||||
EBIT, 2 Yr. CAGR % | 3.41 | 3.5 | 7.01 | 11.44 | 13.25 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 6.6 | 2.29 | -6.2 | 0.42 | 15.48 | |||||
Net Income, 2 Yr. CAGR % | 6.6 | 2.3 | -6.2 | 0.42 | 15.48 | |||||
Normalized Net Income, 2 Yr. CAGR % | 4.84 | 3.03 | 4.44 | 8.11 | 10.33 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 6.61 | 2.3 | -6.2 | 0.41 | 15.47 | |||||
Accounts Receivable, 2 Yr. CAGR % | 4.61 | 1.8 | 16.01 | 20.27 | 19.49 | |||||
Inventory, 2 Yr. CAGR % | 10.42 | 0.41 | 29.92 | 33.04 | 9.28 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 22.48 | -0.84 | 9.3 | 16.73 | 13.95 | |||||
Total Assets, 2 Yr. CAGR % | 12.01 | 0.13 | 21.44 | 22.24 | 13.31 | |||||
Tangible Book Value, 2 Yr. CAGR % | 17.45 | -4.04 | 58.68 | 96.46 | 25.17 | |||||
Common Equity, 2 Yr. CAGR % | 15.09 | 7.36 | 10.08 | 10.48 | 10.17 | |||||
Cash From Operations, 2 Yr. CAGR % | 6.2 | 24.2 | 6.96 | -0.65 | 11.1 | |||||
Capital Expenditures, 2 Yr. CAGR % | 4.79 | -0.55 | 5.99 | 16.56 | 23.86 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | -18.74 | 83.37 | 14.26 | -71.15 | 34.1 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | -18.33 | 97.35 | 16.07 | -55.78 | 19.02 | |||||
Dividend Per Share, 2 Yr. CAGR % | 6.83 | 4.88 | 4.65 | 4.45 | 5.09 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 4 | 5.33 | 7.74 | 12.85 | 14.01 | |||||
Gross Profit, 3 Yr. CAGR % | 4.8 | 6.4 | 8.55 | 12.45 | 12.43 | |||||
EBITDA, 3 Yr. CAGR % | 6.97 | 5.7 | 6.98 | 10.64 | 12.89 | |||||
EBITA, 3 Yr. CAGR % | 7.12 | 5.76 | 7.05 | 10.83 | 12.98 | |||||
EBIT, 3 Yr. CAGR % | 5.19 | 4.3 | 4.95 | 9.63 | 11.44 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 7.12 | 7.3 | -5.39 | 3.11 | 2.57 | |||||
Net Income, 3 Yr. CAGR % | 7.12 | 7.31 | -5.39 | 3.12 | 2.57 | |||||
Normalized Net Income, 3 Yr. CAGR % | 5.71 | 4.35 | 3.86 | 6.51 | 8.71 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 7.13 | 7.31 | -5.39 | 3.1 | 2.57 | |||||
Accounts Receivable, 3 Yr. CAGR % | 3.28 | 7.79 | 6.81 | 18.3 | 18.85 | |||||
Inventory, 3 Yr. CAGR % | 11.94 | 3.54 | 23.18 | 17.23 | 30.34 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 12.06 | 13.86 | 6.08 | 10.27 | 16.38 | |||||
Total Assets, 3 Yr. CAGR % | 9.66 | 9.22 | 12.49 | 15.78 | 22.16 | |||||
Tangible Book Value, 3 Yr. CAGR % | 275.7 | -0.09 | 47.46 | 40.79 | 76.04 | |||||
Common Equity, 3 Yr. CAGR % | 7.5 | 12.77 | 8.86 | 9.74 | 10.75 | |||||
Cash From Operations, 3 Yr. CAGR % | 13.96 | 11.17 | 13.15 | 6.34 | 5.05 | |||||
Capital Expenditures, 3 Yr. CAGR % | 13.38 | 4.12 | 2.63 | 11.77 | 18.81 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 69.58 | 16.62 | 22.26 | -41.53 | -0.76 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 90.98 | 15.76 | 31.15 | -23.09 | -6.38 | |||||
Dividend Per Share, 3 Yr. CAGR % | 7.3 | 6.14 | 4.77 | 4.55 | 4.91 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 6.7 | 6.49 | 7.55 | 9.02 | 9.58 | |||||
Gross Profit, 5 Yr. CAGR % | 7.9 | 7.76 | 8.1 | 9.14 | 9.4 | |||||
EBITDA, 5 Yr. CAGR % | 11.68 | 9.41 | 7.62 | 8.59 | 9.62 | |||||
EBITA, 5 Yr. CAGR % | 11.91 | 9.57 | 7.76 | 8.71 | 9.68 | |||||
EBIT, 5 Yr. CAGR % | 10.91 | 8.23 | 5.91 | 7.1 | 8.2 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 12.3 | 10.21 | 1.58 | 4.49 | 2.46 | |||||
Net Income, 5 Yr. CAGR % | 12.3 | 10.21 | 1.58 | 4.5 | 2.46 | |||||
Normalized Net Income, 5 Yr. CAGR % | 11.31 | 7.69 | 5.2 | 5.84 | 6.4 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 12.29 | 10.22 | 1.59 | 4.49 | 2.46 | |||||
Accounts Receivable, 5 Yr. CAGR % | 8.7 | 8.36 | 8.19 | 12.62 | 11.72 | |||||
Inventory, 5 Yr. CAGR % | 11.92 | 7.57 | 18.81 | 14.46 | 17.42 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 13.59 | 4.91 | 10.95 | 15 | 9.16 | |||||
Total Assets, 5 Yr. CAGR % | 13.04 | 12.53 | 14.23 | 14.26 | 12.82 | |||||
Tangible Book Value, 5 Yr. CAGR % | 14.73 | 24.9 | 166.14 | 30.94 | 38.1 | |||||
Common Equity, 5 Yr. CAGR % | 7.96 | 8.86 | 8.53 | 11.85 | 9.38 | |||||
Cash From Operations, 5 Yr. CAGR % | 10.28 | 13.99 | 11.1 | 6.28 | 12.33 | |||||
Capital Expenditures, 5 Yr. CAGR % | -7.41 | 2.13 | 10.37 | 8.92 | 10.65 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | -1.52 | 15.9 | 44.8 | -33.3 | 26.87 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | -1.07 | 15.78 | 56.49 | -21.22 | 26.16 | |||||
Dividend Per Share, 5 Yr. CAGR % | 11.84 | 9.46 | 6.23 | 5.46 | 4.9 |
- Stock Market
- Equities
- REC Stock
- Financials Recordati
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
















